Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant professor at Tufts University School of Medicine, explains the role of...
Cardiogenic Shock
This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page.
-
-
November 19, 2019 — Since Maquet/Datascope first recalled all of its intra-aortic balloon pumps (...
-
November 4, 2019 — Abbott is recalling its CentriMag Acute Circulatory Support System due to a calibration system error resulting from electromagnetic interference that may cause the pump to slow...
-
William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit, explains data on first 250 patients in the National Cardiogenic Shock Initiative...
News | November 19, 2019
November 19, 2019 — Since Maquet/Datascope first recalled all of its ...
News | Hemodynamic Support Devices | November 04, 2019
November 4, 2019 — Abbott is recalling its CentriMag Acute Circulatory Support System due to a calibration system...
Videos | Cardiogenic Shock | October 08, 2019
Khaldoon Alaswad, M.D., right, director, cardiac catheterization lab, during a complex CTO procedure at Henry Ford Hospital. (Photo by Dave Fornell)
Feature | Henry Ford Hospital | October 01, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders...
Videos | Hemodynamic Support Devices | September 22, 2019
There was a 77 percent increase in survival in cardiogenic shock patients treated using a new protocol in the...
Image courtesy of the Society for Cardiovascular Angiography and Interventions (SCAI).
News | Cardiogenic Shock | May 20, 2019
May 20, 2019 – A newly released expert consensus statement proposes a classification schema for...
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
May 14, 2019 — The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and...
The Abiomed Impella percutaneous heart pump during a procedure at Henry Ford Hospital.
Podcast | Hemodynamic Support Devices | May 02, 2019
This podcast is a discussion with ...
Two device technologies raised concerns in the industry based on recently released clinical data. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.
Blog | Cath Lab | February 20, 2019
Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based...
Sponsored Content | Videos | Heart Failure | February 13, 2019
The Abiomed Impella RP had higher than expected mortality in its post-approval study, much higher than in its pre-market approval study. The vendor and the FDA believe this might be due to poor patient selection and implanting the device too late to aid the patient.
Feature | Hemodynamic Support Devices | February 05, 2019 | Dave Fornell, Editor
The U.S. Food and Drug Administration (FDA) sent a letter to cardiologists this week to explain its evaluation of...
Sponsored Content | Videos | Hemodynamic Support Devices | December 13, 2018
